Please login to the form below

Not currently logged in
Email:
Password:

AVEO's financial head joins ImmunoGen

David Johnston appointed chief financial officer
David Johnston, Immunogen

David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role.

Johnston's switch comes after more than six years at AVEO having joined the company from his role as senior VP of finance corporate planning and analysis at Genzyme.

Other previous roles include VP finance and chief financial officer of Genzyme Biosurgery.

In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen's successes including the breast cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche.

“I am delighted to have Dave join ImmunoGen,” commented ImmunoGen's CEO Daniel Junius.

“His depth of experience in both senior financial positions and in corporate planning makes Dave well-suited to help successfully advance the company to our next stages,” added Junius.

7th January 2014

From: Research, Sales

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...